綠葉製藥(02186.HK)附屬博安生物擬引進戰略投資者
格隆匯8月26日丨綠葉製藥(02186.HK)發佈公吿,2021年8月25日,公司、公司間接附屬公司博安生物、原博安股東(即山東綠葉及博安員工持股計劃實體)及投資者(即高特佳匯科及雲南菲利克斯)訂立認購協議,內容有關投資博安生物,注資總額為人民幣9000萬元。投資者應於博安生物確認所有條件已獲達成後10日內向博安生物全數支付承諾的注資額。認購協議載有向投資者提供若干權利的條文,有關權利包括回購期權,據此,倘發生若干事件,投資者有權要求山東綠葉購買投資者持有的全部博安生物股權。
根據認購協議,(其中包括)博安生物有條件同意發行,而投資者有條件地同意認購股權,該等股權佔完成後的博安生物經擴大註冊資本的1.27%(假設於完成前博安生物將不會發行其他股權),注資總額為現金人民幣9000萬元(相當於每份博安生物註冊資本人民幣14.46元)。認購事項後,博安生物將繼續為集團的附屬公司(由集團持有73.56%),而集團將繼續控制及主導博安生物的發展。
博安生物為集團附屬公司,是一家全面綜合性生物製藥公司。其專門從事治療用抗體開發、製造及商業化,專注於腫瘤、自體免疫、疼痛及內分泌疾病。博安生物的抗體發現活動圍繞三個平台展開,即全人抗體轉基因小鼠及噬菌體展示技術、雙特異性T細胞銜接系統技術、抗體偶聯技術平台。博安生物已開發出10多個擁有國際知識產權保護的創新抗體和8個生物類似藥。
認購事項的所得款項將用作博安生物主營業務的補充營運資金。認購事項的資金將增強博安生物抵禦風險及保持市場競爭力的能力,促進博安生物的長期穩定發展。此外,引進戰略投資者預期將為博安生物的發展與博安生物搶佔行業領先地位的能力帶來協同作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.